In the last trading session, 0.74 million Akero Therapeutics Inc (NASDAQ:AKRO) shares changed hands as the company’s beta touched -0.38. With the company’s per share price at $24.17 changed hands at -$0.96 or -3.82% during last session, the market valuation stood at $1.67B. AKRO’s last price was a discount, traded about -141.54% off its 52-week high of $58.38. The share price had its 52-week low at $11.25, which suggests the last value was 53.45% up since then. When we look at Akero Therapeutics Inc’s average trading volume, we note the 10-day average is 1.87 million shares, with the 3-month average coming to 1.42 million.

Akero Therapeutics Inc (NASDAQ:AKRO) trade information

Instantly AKRO was in red as seen at the end of in last trading. With action -9.95%, the performance over the past five days has been red. The drop to weekly highs of 27.16 subtracted -3.82% to the stock’s daily price. The company’s shares are showing year-to-date upside of 3.51%, with the 5-day performance at -9.95% in the red. However, in the 30-day time frame, Akero Therapeutics Inc (NASDAQ:AKRO) is -4.62% down. Looking at the short shares, we see there were 9.4 million shares sold at short interest cover period of 7.68 days.

Akero Therapeutics Inc (AKRO) estimates and forecasts

Data shows that the Akero Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -47.36% over the past 6 months, a -40.48% in annual growth rate that is considerably lower than the industry average of 12.20%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Akero Therapeutics Inc will fall -81.80%, while the growth in revenue is estimated to hit -66.70% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.03%. The 2024 estimates are for Akero Therapeutics Inc earnings to decrease by -37.28%, but the outlook for the next 5-year period is at -14.60% per year.

AKRO Dividends

Akero Therapeutics Inc is expected to release its next quarterly earnings report between May 13 and May 17.

Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 5.92% of Akero Therapeutics Inc shares while 94.46% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.40%. There are 94.46% institutions holding the Akero Therapeutics Inc stock share, with Janus Henderson Group PLC the top institutional holder. As of Jun 29, 2023, the company held 7.96% of the shares, roughly 4.43 million AKRO shares worth $206.61 million.

Alkeon Capital Management LLC holds the second largest percentage of outstanding shares, with 6.24% or 3.47 million shares worth $161.89 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were ACAP Strategic Fund and Price (T.Rowe) New Horizons Fund. With 1.64 million shares estimated at $76.8 million under it, the former controlled 2.96% of total outstanding shares. On the other hand, Price (T.Rowe) New Horizons Fund held about 2.77% of the shares, roughly 1.54 million shares worth around $71.9 million.